CJM112
Total Payments
$702,712
Transactions
60
Doctors
2
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $461.68 | 4 | 0 |
| 2019 | $128,503 | 13 | 0 |
| 2018 | $422,674 | 20 | 1 |
| 2017 | $151,073 | 23 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $702,712 | 60 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED MULTI CENTER MULTIPLE DOSE STUDY TO ASSESS THE EFFICACY AND SAFETY OF CJM112 IN PATIENTS WITH INADEQUATELY CONTROLLED MODERATE TO SEVERE ASTHMA | Novartis Pharmaceuticals Corporation | $392,619 | 0 |
| A RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED MULTI CENTER STUDY IN PARALLEL GROUPS TO ASSESS THE EFFICACY AND SAFETY OF CJM112 IN PATIENTS WITH MODERATE TO SEVERE INFLAMMATORY ACNE | Novartis Pharmaceuticals Corporation | $211,097 | 0 |
| PIE POC IN HIDRADENITIS SUPPURATIVA | Novartis Pharmaceuticals Corporation | $70,085 | 0 |
| A RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED MULTI CENTER STUDY IN PARALLEL GROUPS TO ASSESS THE EFFICACY AND SAFETY OF CJM112 IN PATIENTS WITH MODERATE TO SEVERE INFLAMMATORY ACNE | NOVARTIS PHARMACEUTICALS CORPORATION | $17,294 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $4,687 | 1 |
| OUTCOMES RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $3,930 | 1 |
| A RANDOMIZED, SUBJECT- AND INVESTIGATOR-BLINDED, PLACEBO CONTROLLED, MULTI-CENTER, MULTIPLE DOSE STUDY TO ASSESS THE EFFICACY AND SAFETY OF CJM112 IN PATIENTS WITH INADEQUATELY CONTROLLED MODERATE TO SEVERE ASTHMA | Novartis Pharmaceuticals Corporation | $3,000 | 0 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $676,801
- NOVARTIS PHARMACEUTICALS CORPORATION $25,911
Product Information
- Type Drug
- Total Payments $702,712
- Total Doctors 2
- Transactions 60
About CJM112
CJM112 is a drug associated with $702,712 in payments to 2 healthcare providers, recorded across 60 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $461.68 was paid across 4 transactions to 0 doctors.
The most common payment nature for CJM112 is "Unspecified" ($702,712, 100.0% of total).
CJM112 is associated with 7 research studies, including "A RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED MULTI CENTER MULTIPLE DOSE STUDY TO ASSESS THE EFFICACY AND SAFETY OF CJM112 IN PATIENTS WITH INADEQUATELY CONTROLLED MODERATE TO SEVERE ASTHMA" ($392,619).